



# May 2025 and August 2025 exceptional surveillance of prostate cancer: diagnosis and management (NICE guideline NG131)

Surveillance report

Published: 30 May 2025

[www.nice.org.uk](http://www.nice.org.uk)

In May 2025 and August 2025, we reviewed this guideline in relation to the [section on localised and locally advanced prostate cancer](#).

## Surveillance decision

In May 2025 it was decided that we will update the guideline around docetaxel and abiraterone for high-risk hormone-sensitive non-metastatic prostate cancer. In August 2025 it was decided that we will update the guideline related to the protocol for active surveillance (AS) for localised prostate cancer.